Company Overview
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- Dec 2025 Revenue of $18.67M (-29.3% YoY); net profit $-64.78M.
- Trailing 12 Months Year-on-year growth — revenue +244.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -14.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -14.39% |
| 1 Year: | 244.20% |
Stock Price Performance
| 1 Year: | +127.32% |
| 6 Months: | +219.18% |
| 3 Months: | +129.56% |
| 1 Month: | -2.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -14.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OABI OmniAb, Inc. R2KR3KPHARMA | 4.66 | -12.94 | $677.52M | 0.00% | -24.23% | -16.95% | -14.39% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 9.62M | 7.20M | 6.91M | 16.92M | 6.95M | 5.48M | 3.80M | 7.61M | 4.17M | 4.15M | 3.90M | 2.24M | 14.43M | 13.41M |
| Operating Income | -2.19K | -170.58K | -8.22M | -12.57M | -14.91M | -8.45M | -19.45M | -20.32M | -22.55M | -16.30M | -19.76M | -18.84M | -16.22M | -18.14M | -7.83M | -6.64M |
| Net Income | -2.19K | -170.58K | -6.28M | -10.28M | -12.60M | -6.10M | -14.73M | -15.74M | -18.96M | -13.63M | -16.37M | -18.20M | -15.88M | -16.52M | -7.71M | -5.86M |
| Diluted EPS | - | -0.01 | -0.08 | -0.12 | -0.15 | -0.06 | -0.15 | -0.16 | -0.19 | -0.13 | -0.16 | -0.17 | -0.15 | -0.14 | -0.06 | -0.05 |
| R&D Expense | - | - | 10.77M | 11.48M | 13.19M | 13.76M | 14.13M | 13.87M | 14.55M | 13.94M | 13.32M | 12.60M | 10.86M | 10.38M | 9.64M | 9.59M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.75M | 59.08M | 34.16M | 26.39M | 18.67M |
| Operating Income | -35.61M | -26.65M | -69.42M | -74.50M | -68.97M |
| Net Income | -27.04M | -22.33M | -50.62M | -62.03M | -64.78M |
| Diluted EPS | -0.33 | -0.26 | -0.51 | -0.61 | -0.57 |
| R&D Expense | 39.23M | 48.36M | 56.52M | 55.11M | 47.75M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Feb 2021 | Dec 2021 | Nov 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 304.46M | 393.11M | 421.21M | 375.23M | 325.56M | 300.91M |
| Total Equity | 235.54M | 0 | 234.31M | - | 341.37M | 314.58M | 287.62M | 267.03M |
| Cash & Equivalents | - | - | 0 | 98.08M | 33.39M | 16.36M | 27.60M | 25.52M |
| Total Liabilities | - | - | 70.16M | 67.13M | 79.84M | 60.64M | 37.94M | 33.89M |
| Current Liabilities | - | - | 20.58M | 12.26M | 26.02M | 23.12M | 15.09M | 16.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -5.67M | -3.59M | 2.35M | -39.66M | -36.45M |
| Investing Cash Flow | -4.03M | -73.31M | -18.38M | 37.88M | 6.47M |
| Financing Cash Flow | 9.70M | 110.74M | -892.00K | 13.02M | 27.91M |
| Capital Expenditure | -4.07M | -17.17M | -1.64M | -1.88M | -565.00K |
| Free Cash Flow | -9.74M | -20.75M | 703.00K | -41.54M | -37.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | -102.5% | -45.1% | -203.2% | -282.3% | -369.5% |
| Net Margin % | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
| ROE % | -11.5% | -6.5% | -16.1% | -21.6% | -24.3% |
| ROCE % | -12.5% | -6.7% | -19.7% | -24.0% | -24.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Whitefort Capital Management, LP | 7.07% | 10.25M | $49.09M |
| 2 | Blackrock Inc. | 6.14% | 8.90M | $42.62M |
| 3 | Nomura Holdings Inc. | 3.47% | 5.03M | $24.08M |
| 4 | Cadian Capital Management, LP | 2.91% | 4.21M | $20.17M |
| 5 | Vanguard Capital Management LLC | 2.66% | 3.85M | $18.45M |
| 6 | Geode Capital Management, LLC | 1.99% | 2.88M | $13.81M |
| 7 | Rice, Hall, James & Associates LLC | 1.80% | 2.61M | $12.50M |
| 8 | Private Management Group, Inc. | 1.62% | 2.34M | $11.23M |
| 9 | State Street Corporation | 1.47% | 2.13M | $10.22M |
| 10 | Dimensional Fund Advisors LP | 0.87% | 1.26M | $6.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OABI
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPZDdoQldjREJ6NUNnOWFhU3NLdjY1NmVTV05MTnNUNUswWldPLS0xbHZodFUtY3k1bmtTMWZrUmpvc2VfSTc5WGRBQzJDUVBEZ1Bjb0JMcTRnbGJsMEFaR1hDYVZqa1VybndCY0E5TjhwcFlXd1FYRlo3ei03amJsdmlSM09hSXVQRXV2bQ…
OmniAb (NASDAQ:OABI) Passes Minervini Trend Template and High-Growth Momentum Screen - ChartMill
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNcWpFaTJqRHlpczNuOVE5WHFWamJxOUtENE0wejlKT3dFNHpMa2tpdVZRNGJ2R3lHTDZ0R1NzVkR6eE9saWFYdHdQb19fLTZmMVIyN1AzV2tmbXdueVVWbjljdmo1bi1GVVUzSjhlUTZMT09VQmw0OVlkSkdWeWFuajZCcEZVREZtTkI2WU…
Why Is Omniab Stock Rallying After Eli Lilly Deal? - Benzinga
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQUnYzRWdGb3Z6bk03THo1UVVpcUxOaHJCaXdxOFNYRHU2bnMxeVhyZGR5bGJmZHlWdHhIdU5pREQxQVlCWE16YmVFcnBlRFNxUUxibkZXaUo0UXZuTmRuQ2lUdUt5WGFWeVJkWjZhdzZaZlN4bVhUN2xyQkIzUHVHMjk1b3k2REt0Ync2bW…
OABI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBTcU5NNmNWbWpBbkVfc0NWSjlibUIxbVVfcGNGLXpsYTlqS3FPY290dVFvNWU1VTBkNXVmNmt3Nll3QW9JemExSC1ZczJmSWEtMkhyVmJYQV9sNlVLUE9VbGtqbnF3ZkVhVXZuU196WjNFdW96RlZESlJn?oc=5" target="_blank">OAB…
OmniAb: Lilly-Style Partners Paying Attention To This Early-Stage Biotech (NASDAQ:OABI) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQS3k3aVJlUjBUcjBoS1o4OFF5MWtfLU9jRG9QMkJDYkN3TDQzUW9qX0V4R1ZOdTFZbl8xcldKbkNRemJuWFdZbGdrRXAwTUxrTEhhZ3ZJMUpKd3VYaURKSUgxUHdfcDdTRkdtcmtKQllSMFJrdEFKeW91ZlBpM0JubVNWSm5PRWxfM2txMW…
OmniAb (NasdaqGM:OABI) Stock Forecast & Analyst Predictions - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQcnJpTzRrcVVnRG05SWpYeHVnMnlTbW1Zdk1VV21qalhJckloVkhKT2VsMlBIcDVvYVl6VG5hQ0hJMmNoWms1dHRrQUhzSjQ3dDBBWjFzY2ZpTEp5Q0J0NHJiTkU4bk1FUFRqRzhkbVBtYVJkRHlvVC1ucEcteWNvbGZMaGRXekMx?oc=5"…
OABI — Frequently Asked Questions
What is the current share price of OmniAb, Inc. (OABI)?
As of 2026-10-23 16:27 PDT, OmniAb, Inc. (OABI) trades at $4.66 on NasdaqGM. Its 52-week range is $1.36 to $5.04.
What is the market capitalisation of OABI?
OmniAb, Inc. (OABI) has a market capitalisation of $677.52M on NasdaqGM.
What is the P/E ratio of OABI?
OABI trades at a trailing price-to-earnings (P/E) ratio of -12.94. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.50.
What is the return on equity (ROE) of OABI?
OABI has a return on equity (ROE) of -16.95%. Its return on capital employed (ROCE) is -24.23%.
Is OABI a good stock to buy?
This page provides a data-driven analysis of OmniAb, Inc. (OABI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.